Yuanda Pharmaceutical (00512) rose more than 6% in the intraday period. As of press release, it rose 4.94% to HK$4.25, with a turnover of HK$21.15,900.
The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) rose more than 6% in the intraday period. As of press release, it had risen 4.94% to HK$4.25, with a turnover of HK$21.15,900.
According to the news, according to the “China Nuclear Power Group” official Weiwei article, China successfully mass-produced carbon-14 isotopes using commercial nuclear power reactors for the first time, marking that China has achieved full localization of carbon-14 supply. After the carbon-14 target is completed, it will be supplied to the market at the end of 2024 after back-end processing. The output can fully meet domestic demand. It will strongly drive the development of China's isotope application industry chain, further establish and improve industry-university-research cooperation to carry out commercial reactor irradiation to produce isotopes, promote and drive downstream medical enterprises to develop advanced nuclear drugs and nuclear medicine industries, and provide strong support for the development of the domestic isotope application industry.
According to reports, in 2023, Telix Pharmaceuticals Limited, an important strategic partner in the field of radionuclide conjugated drugs (RDC) of Yuanda Pharmaceuticals, submitted a biological product marketing license application (BLA) to the US FDA for TLx250-cdx, a globally innovative RDC drug used to diagnose renal clear cell carcinoma (cCRCC). TLx250-cdx is a globally innovative RDC drug for the diagnosis of cCRCC. It targets carbonic anhydrase IX (CA9), which is overexpressed in ccRCC and many other cancers.